Endo International PLC (ENDP) Receives Coverage Optimism Rating of 0.22

Media coverage about Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endo International PLC earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6932970235843 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s analysis:

Shares of Endo International PLC (NASDAQ:ENDP) traded down 0.23% during midday trading on Friday, hitting $8.60. The stock had a trading volume of 7,448,532 shares. The stock’s market cap is $1.92 billion. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $23.98. The firm has a 50 day moving average price of $8.88 and a 200-day moving average price of $10.89.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. Endo International PLC’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.86 EPS. Equities analysts predict that Endo International PLC will post $3.52 EPS for the current fiscal year.

Several research firms recently weighed in on ENDP. Piper Jaffray Companies reiterated a “hold” rating and set a $9.00 target price on shares of Endo International PLC in a research report on Sunday. Mizuho reiterated a “buy” rating and set a $14.00 target price (down from $19.00) on shares of Endo International PLC in a research report on Tuesday, September 12th. ValuEngine downgraded Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub upgraded Endo International PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Finally, Canaccord Genuity set a $10.00 target price on Endo International PLC and gave the company a “hold” rating in a research report on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the stock. Endo International PLC currently has a consensus rating of “Hold” and a consensus price target of $14.33.

TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/09/17/endo-international-plc-endp-receives-coverage-optimism-rating-of-0-22.html.

In other Endo International PLC news, CFO Blaise Coleman acquired 6,500 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was bought at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the acquisition, the chief financial officer now owns 13,729 shares in the company, valued at $108,321.81. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Terrance J. Coughlin acquired 20,000 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $7.70 per share, with a total value of $154,000.00. Following the acquisition, the chief operating officer now owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 36,000 shares of company stock valued at $279,460. 0.50% of the stock is owned by insiders.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Insider Buying and Selling by Quarter for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply